58 related articles for article (PubMed ID: 16785987)
1. Fusion tyrosine kinases: a result and cause of genomic instability.
Penserga ET; Skorski T
Oncogene; 2007 Jan; 26(1):11-20. PubMed ID: 16785987
[TBL] [Abstract][Full Text] [Related]
2. Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure.
Vellichirammal NN; Albahrani A; Guda C
Transl Lung Cancer Res; 2022 Oct; 11(10):2022-2039. PubMed ID: 36386463
[TBL] [Abstract][Full Text] [Related]
3. Dual Kinase Targeting in Leukemia.
Mologni L; Marzaro G; Redaelli S; Zambon A
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401428
[TBL] [Abstract][Full Text] [Related]
4. Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukemia: A retrospective study.
Ammar M; Ben Mahmoud L; Medhaffar M; Ghozzi H; Sahnoun Z; Hakim A; Mseddi M; Elloumi M; Zeghal K
J Clin Lab Anal; 2020 Feb; 34(2):e23050. PubMed ID: 31617242
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients.
Dhangar S; Shanbhag V; Shanmukhaiah C; Vundinti BR
Mol Biol Rep; 2019 Oct; 46(5):4997-5003. PubMed ID: 31286393
[TBL] [Abstract][Full Text] [Related]
6. Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia.
Xie J; Chen J; Wang B; He X; Huang H
Oncol Lett; 2019 Jan; 17(1):999-1007. PubMed ID: 30655859
[TBL] [Abstract][Full Text] [Related]
7. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Bourgeais J; Ishac N; Medrzycki M; Brachet-Botineau M; Desbourdes L; Gouilleux-Gruart V; Pecnard E; Rouleux-Bonnin F; Gyan E; Domenech J; Mazurier F; Moriggl R; Bunting KD; Herault O; Gouilleux F
Oncotarget; 2017 Jun; 8(26):41876-41889. PubMed ID: 27566554
[TBL] [Abstract][Full Text] [Related]
9. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Dasgupta Y; Koptyra M; Hoser G; Kantekure K; Roy D; Gornicka B; Nieborowska-Skorska M; Bolton-Gillespie E; Cerny-Reiterer S; Müschen M; Valent P; Wasik MA; Richardson C; Hantschel O; van der Kuip H; Stoklosa T; Skorski T
Blood; 2016 Apr; 127(17):2131-43. PubMed ID: 26864341
[TBL] [Abstract][Full Text] [Related]
10. Characterization of chromosomal translocation breakpoint sequences in solid tumours: "an in silico analysis".
Daga A; Ansari A; Rawal R; Umrania V
Open Med Inform J; 2015; 9():1-8. PubMed ID: 25972994
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
Gibbons DL; Pricl S; Posocco P; Laurini E; Fermeglia M; Sun H; Talpaz M; Donato N; Quintás-Cardama A
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3550-5. PubMed ID: 24550512
[TBL] [Abstract][Full Text] [Related]
12. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Petrola MJ; de Castro AJ; Pitombeira MH; Barbosa MC; Quixadá AT; Duarte FB; Gonçalves RP
Rev Bras Hematol Hemoter; 2012; 34(5):352-5. PubMed ID: 23125543
[TBL] [Abstract][Full Text] [Related]
14. Congenital fibrosarcoma and history of prenatal exposure to petroleum derivatives.
Ortega-García JA; Soldin OP; López-Hernández FA; Trasande L; Ferrís-Tortajada J
Pediatrics; 2012 Oct; 130(4):e1019-25. PubMed ID: 22945410
[TBL] [Abstract][Full Text] [Related]
15. Treatments for chronic myeloid leukemia: a qualitative systematic review.
Ferdinand R; Mitchell SA; Batson S; Tumur I
J Blood Med; 2012; 3():51-76. PubMed ID: 22915985
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.
Kong JH; Mun YC; Kim S; Choi HS; Kim YK; Kim HJ; Moon JH; Sohn SK; Kim SH; Jung CW; Dennis Kim DH
Int J Hematol; 2012 Sep; 96(3):327-33. PubMed ID: 22821389
[TBL] [Abstract][Full Text] [Related]
17. The SAM domain of human TEL2 can abrogate transcriptional output from TEL1 (ETV-6) and ETS1/ETS2.
Vivekanand P; Rebay I
PLoS One; 2012; 7(5):e37151. PubMed ID: 22615925
[TBL] [Abstract][Full Text] [Related]
18. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.
Thanasopoulou A; Stravopodis DJ; Dimas KS; Schwaller J; Anastasiadou E
PLoS One; 2012; 7(2):e31007. PubMed ID: 22363533
[TBL] [Abstract][Full Text] [Related]
19. Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.
Young LC; Bone KM; Wang P; Wu F; Adam BA; Hegazy S; Gelebart P; Holovati J; Li L; Andrew SE; Lai R
Am J Pathol; 2011 Jul; 179(1):411-21. PubMed ID: 21703420
[TBL] [Abstract][Full Text] [Related]
20. Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate.
Nadarajan VS; Phan CL; Ang CH; Liang KL; Gan GG; Bee PC; Zakaria Z
Int J Hematol; 2011 Apr; 93(4):465-473. PubMed ID: 21387093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
